Life after the lead asset: Advancing an early-stage pipeline

Arvinas CEO Randy Teel details the strategic pivot from a late-stage commercial focus to an early-stage, platform-driven pipeline. Following the FDA approval and subsequent outlicensing of their lead asset, the company reallocated capital toward Phase 1 programs in oncology and neurology. Success during such inflection points requires a pre-existing, robust pipeline that allows for seamless transitions. Arvinas balances risk by blending well-validated targets with novel, high-impact indications, such as neurodegenerative disorders. Strategic outlicensing serves as a vital lever, enabling the company to maintain focus on its core expertise in protein degradation while ensuring that diverse therapeutic programs reach patients faster through external partnerships. This approach maximizes long-term value for stakeholders and ensures the organization remains agile as it evolves from a single-asset focus to a broader, multi-program clinical entity.